Could a common blood pressure drug help dementia with lewy bodies?
NCT ID NCT04760860
First seen Jun 27, 2026 ยท Last updated Jun 27, 2026
Summary
This early-stage trial will test whether terazosin, a drug currently used for high blood pressure and enlarged prostate, is safe and tolerable for people with dementia with Lewy bodies. Forty participants will receive either terazosin or a placebo for 15 weeks. The study focuses on side effects and how well people stick with the treatment, not on whether it improves symptoms.
What this could mean
Our plain-language read of the trial. This is informational only โ not medical advice or a prediction.
- Active substance
- Terazosin hydrochloride (a drug usually used for high blood pressure or enlarged prostate)
- What this could lead to
- If it works, this could point toward a new way to ease motor symptoms in dementia with Lewy bodies.
- What could go wrong
- This is a very early, small trial (40 people) focused on safety and tolerability, not on proving the drug works. It may fail to show benefit or cause side effects like low blood pressure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DEMENTIA WITH LEWY BODIES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Iowa
Iowa City, Iowa, 52252, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Skin, speech, and brain scans may unmask hidden neurodegeneration
- Can sound waves soothe Dementia's emotional turmoil?
- Cancer drug shows promise for treating lewy body dementia
- Could tiny doses of radiation slow Alzheimer's? a new trial investigates
- Brain scans track Alzheimer's clues over decades
- Can a One-Time bone drug shield Parkinson's patients from fractures?